Literature DB >> 11747901

Gabapentin is not a GABAB receptor agonist.

C Lanneau1, A Green, W D Hirst, A Wise, J T Brown, E Donnier, K J Charles, M Wood, C H Davies, M N Pangalos.   

Abstract

Recent experiments have demonstrated that formation of functional type B gamma-aminobutyric acid (GABA(B)) receptors requires co-expression of two receptor subunits, GABA(B1) and GABA(B2). Despite the identification of these subunits and a number of associated splice variants, there has been little convincing evidence of pharmacological diversity between GABA(B) receptors comprising different subunit combinations. However, Ng et al. [Mol. Pharmacol., 59 (2000) 144] have recently suggested a novel and important pharmacological difference between GABA(B) receptor heterodimers expressing the GABA(B1a) and GABA(B1b) receptor subunits. This study suggested that the antiepileptic GABA analogue gabapentin (Neurontin) is an agonist at GABA(B) receptors expressing the GABA(B1a) but not the GABA(B1b) receptor subunit. The importance of this finding with respect to identifying novel GABA(B) receptor subunit specific agonists prompted us to repeat these experiments in our own [35S]-GTPgammaS binding and second messenger assay systems. Here we report that gabapentin was completely inactive at recombinant GABA(B) heterodimers expressing either GABA(B1a) or GABA(B1b) receptor subunits in combination with GABA(B2) receptor subunits. In addition, in both CA1 and CA3 pyramidal neurones from rodent hippocampal slices we were unable to demonstrate any agonist-like effects of gabapentin at either pre- or post-synaptic GABA(B) receptors. In contrast, gabapentin activated a GABA(A) receptor mediated chloride conductance. Our data suggest that gabapentin is not a GABA(B)-receptor agonist let alone a GABA(B) receptor subunit selective agonist.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11747901     DOI: 10.1016/s0028-3908(01)00140-x

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  29 in total

1.  The alpha2delta ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit alpha2delta-2.

Authors:  Alexandra Tran-Van-Minh; Annette C Dolphin
Journal:  J Neurosci       Date:  2010-09-22       Impact factor: 6.167

2.  Gabapentin attenuates hyperexcitability in the freeze-lesion model of developmental cortical malformation.

Authors:  Lauren Andresen; David Hampton; Amaro Taylor-Weiner; Lydie Morel; Yongjie Yang; Jamie Maguire; Chris G Dulla
Journal:  Neurobiol Dis       Date:  2014-08-23       Impact factor: 5.996

3.  Not another gabapentin mechanism!

Authors:  Graeme J Sills
Journal:  Epilepsy Curr       Date:  2005 Mar-Apr       Impact factor: 7.500

4.  Vigabatrin, a GABA transaminase inhibitor, reversibly eliminates tinnitus in an animal model.

Authors:  Thomas J Brozoski; T Joseph D Spires; Carol A Bauer
Journal:  J Assoc Res Otolaryngol       Date:  2007-01-13

5.  Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.

Authors:  Rebecca E Balter; Ziva D Cooper; Margaret Haney
Journal:  Curr Addict Rep       Date:  2014-06-01

6.  Pregabalin abuse and dependence in Germany: results from a database query.

Authors:  Maximilian Gahr; Roland W Freudenmann; Christoph Hiemke; Makus A Kölle; Carlos Schönfeldt-Lecuona
Journal:  Eur J Clin Pharmacol       Date:  2013-01-05       Impact factor: 2.953

Review 7.  GABA pharmacology: the search for analgesics.

Authors:  Kenneth E McCarson; S J Enna
Journal:  Neurochem Res       Date:  2014-02-15       Impact factor: 3.996

8.  Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels.

Authors:  Rían W Manville; Geoffrey W Abbott
Journal:  Mol Pharmacol       Date:  2018-07-18       Impact factor: 4.436

9.  Gabapentin enacarbil - clinical efficacy in restless legs syndrome.

Authors:  Pinky Agarwal; Alida Griffith; Henry R Costantino; Narendra Vaish
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

10.  Acute effects of gabapentin on laboratory measures of aggressive and escape responses of adult parolees with and without a history of conduct disorder.

Authors:  Don R Cherek; Oleg V Tcheremissine; Scott D Lane; Cynthia J Pietras
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.